by Sophia George
Providing equal access to care will not by itself equalize outcomes between Black and white women.
Women from the African diaspora are disproportionately affected by high-grade and aggressive ovarian tumours. In the United States, mortality due to … Read more
by Alison Kanski
NEW YORK – Gynecologic oncology fellows at Memorial Sloan Kettering have developed an online resource for cancer patients, family members, and doctors aiming to raise awareness of genetic cancer risks and spur more testing among relatives for … Read more
By Krista Conger
Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
Women newly diagnosed with breast or ovarian cancer who are also … Read more
Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1… Read more
By Christina Bennett, MS
The number of genes tested for ovarian and breast cancer has grown in recent years, but most patients do not undergo testing. Thus, variant-of-unknown-significance (VUS) results are common, especially among minority populations, according to the results … Read more
Receiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.
By
Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of
… Read moreBy Sandee LaMotte, CNN
A genetic test used to detect common traits many people share is not reliable in identifying rare disease-causing variations, such as those that can predict breast and ovarian cancer, a new study has found.
The SNP … Read more
Although ovarian cancer is the fifth-leading cause of death from cancer in women, scientists don’t have a good handle on how it forms. Now a new study suggests that a microRNA—a molecule made by cells to turn genes on … Read more
By Diana Swift
Population screening found to be cost-effective for higher income countries
Screening entire populations of women for mutations in breast and ovarian cancer susceptibility genes could prevent hundreds of thousands of cases in the U.S., and millions globally, … Read more
For years, The Clearity Foundation has emphasized the importance of tumor profiles/blueprints for informing decisions about treatment for ovarian cancer. Yet, genetic and tumor biomarker testing are not universally performed despite evidence that positive results in these tests could suggest … Read more
By Stand Up To Cancer
Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don’t get tested. A collaborative Stand Up … Read more
By Susan Moench, PhD, PA-C
Results of a randomized clinical trial evaluating video-assisted genetic counseling followed by either formal genetic counseling or direct referral for genetic testing in women with ovarian/fallopian/peritoneal cancer receiving adjuvant therapy showed that a significantly higher … Read more
By Will Boggs MD
NEW YORK (Reuters Health) – Pathogenic variants in RAD51C and RAD51D are associated with an increased risk of ovarian and breast cancer, researchers report.
“RAD51C and RAD51D are included in cancer gene panels that are widely … Read more
By Susan Moench, PhD, PA-C
A central tenant of a recently issued American Society of Clinical Oncology (ASCO) guideline is that all women with a diagnosis of epithelial ovarian cancer should be offered testing for specific germline mutations associated with … Read more
By Christina Bennett, MS
Germline PALB2 pathogenic variants were associated with an increased risk for female breast cancer, male breast cancer, ovarian cancer, and pancreatic cancer, and these risks varied by age, according to data from an international study … Read more
By Colin C. Pritchard
People of all sexes can have risk genes that are often assumed to affect only women. Renaming the syndrome should aid cancer prevention and treatment, argues Colin C. Pritchard.
I recently had a conversation with my … Read more
In what they claim is the first large-scale systematic analysis of thousands of gene fusions in human cancers, scientists have identified a gene fusion that could represent a novel drug target for multiple cancers. Through their studies, the largely U.K.-based … Read more
A team of researchers at UCLA’s Jonsson Comprehensive Cancer, Cedars-Sinai Cancer and Dana-Farber Cancer Institute have newly identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer. The findings, published today in … Read more
Two of the key points this article touches on refer to finding a clinical trial and seeking mental health support. At Clearity, we can help! Check out our Clinical Trial Finder, as well as Steps Through OC, a … Read more
By Krista Conger
A large study of women with breast and ovarian cancer has revealed significant gaps between national guidelines for genetic testing and actual testing practices, according to researchers from Stanford and five other institutions.
Fewer than a quarter … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
